Cadonilimab NCT07446257 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 15 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Early Phase 1

Clinical phase

Recruiting

Recruitment status

not reported

Planned enrollment

2029-09-01

Primary-completion proxy

Executive view

NCT07446257 evaluates Cadonilimab in Hepatocellular Carcinoma. The disclosed sponsor is The University of Texas Southwestern Medical Center, the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Incidence of treatment-related delay of surgical resection >28 days from expected surgery date., assessed over 28 days after the expected surgery date (day 5 of cycle 3 for all treatment arms).

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07446257 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Hepatocellular Carcinoma landscape. Drug & Asset MCP drug_fetch was queried for Cadonilimab, while Company & Deal Intelligence MCP organization_fetch was queried for The University of Texas Southwestern Medical Center.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07446257	Cadonilimab	Early Phase 1 / Recruiting	The University of Texas Southwestern Medical Center	United States	Incidence of treatment-related delay of surgical resection >28 days from expected surgery date. 28 days after the expected surgery date (day 5 of cycle 3 for all tre…	2029-09-01
NCT07558200	TEV-56278	Phase 1 / Not yet recruiting	Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.	China	Incidence and severity of dose-limiting toxicities (DLTs) in Phase Ia First 2 cycles after first dose (each cycle = 14 days; approximately…	2030-04-23
NCT07557251	Sintilimab	Phase 1 / Recruiting	Cancer Hospital Chinese Academy of Medical Sciences	China	Incidence and type of dose-limiting toxicities (DLTs) Up to 30 days post last dose	2028-12-01
NCT07553767	Tenofovir Alafenamide Fumarate	Early Phase 1 / Not yet recruiting	Ningbo No. 2 Hospital	China	Concentration of Hepatitis B Surface Antigen (Hepatitis B Surface Antigen, HBsAg) Baseline, Weeks 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192, 216…	2034-12-31
NCT07551778	Cetuximab	Phase 1/2 / Not yet recruiting	BOE Technology Group Co., Ltd.	Geography not reported	Dose-Limiting Toxicity (DLT) During the first treatment cycle (21 days for Cohorts 1&3, 14 days fo…	2028-04-01

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07446257 is a Early Phase 1, recruiting study with not reported planned participants. Allocation is Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment.

The primary endpoint is “Incidence of treatment-related delay of surgical resection >28 days from expected surgery date.” over “28 days after the expected surgery date (day 5 of cycle 3 for all treatment arms).” The retrieved endpoint description is: Safety is measured as the proportion of participants who experience a treatment-related delay in the planned surgical resection, defined as surgery occurring more than 28 days after the expected surgery date (day 5 of cycle 3 for all treatment arms).

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

0 recent result records were selected as contextual evidence for Hepatocellular Carcinoma. These records do not establish direct evidence for NCT07446257 unless the registration number matches.

Indexed evidence status

No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Cadonilimab is indexed as Bispecific antibody with CTLA4 x PD-1 biology and a global stage of Approved. The asset profile lists Zhongshan Kangfang Biopharma Co. Ltd. as an originator or developer.

The University of Texas Southwestern Medical Center is indexed in an unreported country with the website http://www.utsouthwestern.edu. UT Southwestern Medical Center is one of the country's leading academic medical centers, patient-care providers, and research institutions. The record lists 73 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Cadonilimab is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07446257
Protocol source: https://clinicaltrials.gov/study/NCT07446257
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 15 October 2026.

Cadonilimab in Hepatocellular Carcinoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Incidence of treatment-related delay of surgical resection >28 days from expected surgery date. and 2029-09-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP